Lawlor Sally Bridget 4

What Happened Sally Bridget Lawlor, Chief Financial Officer of Quoin Pharmaceuticals (QNRX), was granted a derivative award reported as 85,250 American Depositary Shares (ADSs) on Feb 4, 2026, listed at $0.00. The filing treats this as a compensation grant (derivative acquisition), not an open-market purchase or sale. Per the filing, each ADS represents 35 ordinary shares, so the award covers 2,983,750 underlying ordinary shares (85,250 × 35). The award vests over four years (see vesting schedule below).

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (timely filing).
• Transaction type/code: Award/Grant (derivative acquisition, code A).
• Amount: 85,250 ADSs reported at $0.00; equals 2,983,750 ordinary shares (each ADS = 35 ordinary shares).
• Vesting: 20% vests Feb 4, 2027; 20% vests Feb 4, 2028; 20% vests Feb 4, 2029; 40% vests Feb 4, 2030 (footnote F2).
• Footnote F1: Number and exercise price are stated in ADSs; each ADS = 35 ordinary shares.
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: Filed within two business days of the transaction date (not reported late).

Context This was a compensation award to the CFO that vests over multiple years — not an immediate purchase or sale. Such grants are routine executive compensation and do not by themselves indicate current buying or selling pressure. Retail investors may monitor future filings for exercises, sales, or additional details on exercise price and fair value that could affect dilution or insider ownership.